Selami Demirci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Selami Demirci has a total of 185 co-authors. Here are the top co-authors by number of shared publications:
- John F. Tisdale
Cellular and Molecular Therapeutics Branch (CMTB), National Heart Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, 20814 USA
8 shared publications - John F. Tisdale
Molecular and Clinical Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA
8 shared publications Alexis Leonard
Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute/National Institutes of Health, Bethesda, MD
7 shared publicationsAllen E. Krouse
Translational Stem Cell Biology Branch, NHLBI, NIH, Bethesda, MD 20814, USA
5 shared publicationsKhaled Essawi
Department of Medical Laboratory Technology, College of Applied Medical Sciences, Jazan University, Gizan 45142, Saudi Arabia
5 shared publicationsNaoya Uchida
National Heart, Lung, and Blood Institute (NHLBI)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), Bethesda, MD 20814, USA
5 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 37 (4)
Beyond repressor disruption: Designing activator motifs to boost fetal hemoglobin
- 28 October 2026
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 37 (4)
Open AccessBeyond repressor disruption: Designing activator motifs to boost fetal hemoglobin
- Open Access
- 17 August 2026
- Published by Elsevier in Blood Red Cells & Iron
- Vol. 2 (4)
Mixed myeloid chimerism and hemolytic markers after nonmyeloablative HCT for sickle cell disease
- 17 August 2026
- Published by Elsevier in Blood Red Cells & Iron
- Vol. 2 (4)
Open AccessMixed myeloid chimerism and hemolytic markers after nonmyeloablative HCT for sickle cell disease
- Open Access
- 6 April 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (7) , 2479-2494
Clonal dynamics, tolerance, and adverse events after CD45-ADC–conditioned autologous HSPC transplantation in macaques
Compared with total body irradiation (TBI) or chemotherapy, antibody-drug conjugates (ADCs) offer a more targeted and potentially less toxic method for transplantation conditioning. CD45-ADC targets a pan-leukocyte antigen expressed on hematopoietic stem and progenitor cells (HSPCs) and immune cells, offering a promising strategy for gene therapy or allogeneic transplantation. We evaluated reconstitution, clonal dynamics, immune tolerance, and toxicity after conditioning with a DGN549-C–conjugated CD45-ADC followed by autologous transplantation in rhesus macaques. Two doses (0.2 and 0.3 mg/kg) were tested, with HSPC infusion 10 days after conditioning. All animals received barcoded, copepod green fluorescent protein (CopGFP)-expressing lentivirally transduced HSPCs. Both doses resulted in profound depletion of HSPCs and expected cytopenias, with incomplete lymphocyte depletion. With 0.2 mg/kg CD45-ADC conditioning, 2 animals showed robust multilineage engraftment with gene-modified cells and high clonal diversity, comparable with TBI. However, CopGFP+ cell levels and clonal diversity declined at 4 to 8 months, accompanied by development of anti-CopGFP antibodies, suggesting immune rejection. Incomplete T-cell depletion may have contributed. Notably, this rejection was slower and less complete than that after busulfan conditioning, suggesting partial immune tolerance. Dexamethasone treatment in 1 animal reversed rejection and stabilized CopGFP+ levels for >2 years. At 0.3 mg/kg CD45-ADC, 2 animals developed severe respiratory distress 4 to 6 days after transplantation, requiring humane euthanasia, accompanied by elevated inflammatory cytokines. This severe syndrome was not seen in 9 additional animals conditioned with CD45-ADC. These findings highlight the importance of preclinical evaluation of experimental therapeutics. Combining lower-dose CD45-ADC with immune suppression may enable durable engraftment in settings of alloantigen or neoantigen expression.
- 6 April 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (7) , 2479-2494
Open AccessClonal dynamics, tolerance, and adverse events after CD45-ADC–conditioned autologous HSPC transplantation in macaques
Compared with total body irradiation (TBI) or chemotherapy, antibody-drug conjugates (ADCs) offer a more targeted and potentially less toxic method for transplantation conditioning. CD45-ADC targets a pan-leukocyte antigen expressed on hematopoietic stem and progenitor cells (HSPCs) and immune cells, offering a promising strategy for gene therapy or allogeneic transplantation. We evaluated reconstitution, clonal dynamics, immune tolerance, and toxicity after conditioning with a DGN549-C–conjugated CD45-ADC followed by autologous transplantation in rhesus macaques. Two doses (0.2 and 0.3 mg/kg) were tested, with HSPC infusion 10 days after conditioning. All animals received barcoded, copepod green fluorescent protein (CopGFP)-expressing lentivirally transduced HSPCs. Both doses resulted in profound depletion of HSPCs and expected cytopenias, with incomplete lymphocyte depletion. With 0.2 mg/kg CD45-ADC conditioning, 2 animals showed robust multilineage engraftment with gene-modified cells and high clonal diversity, comparable with TBI. However, CopGFP+ cell levels and clonal diversity declined at 4 to 8 months, accompanied by development of anti-CopGFP antibodies, suggesting immune rejection. Incomplete T-cell depletion may have contributed. Notably, this rejection was slower and less complete than that after busulfan conditioning, suggesting partial immune tolerance. Dexamethasone treatment in 1 animal reversed rejection and stabilized CopGFP+ levels for >2 years. At 0.3 mg/kg CD45-ADC, 2 animals developed severe respiratory distress 4 to 6 days after transplantation, requiring humane euthanasia, accompanied by elevated inflammatory cytokines. This severe syndrome was not seen in 9 additional animals conditioned with CD45-ADC. These findings highlight the importance of preclinical evaluation of experimental therapeutics. Combining lower-dose CD45-ADC with immune suppression may enable durable engraftment in settings of alloantigen or neoantigen expression.
- Open Access
- 14 January 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (2) , 289-300
Comparative analysis of CRISPR-Cas9, lentiviral transduction, and base editing for sickle cell disease in a murine model
Sickle cell disease (SCD) is a red blood cell disorder caused by a mutation in the β-globin gene, leading to sickle hemoglobin polymerization under low oxygen conditions. Both CRISPR-Cas9 editing and lentiviral transduction have shown promising clinical outcomes, but it remains unclear which approach is superior. Alternatively, new editing tools such as base editing may also be promising and reduce risks of genotoxicity. To compare these approaches, we studied them in an immunocompromised mouse model. We optimized ex vivo conditions in CD34+ hematopoietic stem and progenitor cells (HSPC) and infused edited SCD HSPC into busulfan-conditioned nonirradiated NOD,B6.SCID Il2rγ−/−KitW41/W41 (NBSGW) mice. Ex vivo analysis confirmed successful editing and transduction. At 16 weeks, bone marrow analysis showed similar human CD45+ cell engraftment across all groups (75%-90%). In the competitive transplantation group, there was a lower amount of B-cell lymphoma/leukemia 11A enhancer editing than base editing and lentiviral transduction. A secondary transplantation model yielded similar results. An antisickling assay showed significantly higher red blood cell sickling reduction in the base editing, transduction, and competitive transplantation groups compared to CRISPR-Cas9. In conclusion, although all methods showed therapeutic potential, base editing and lentiviral transduction provided superior outcomes over CRISPR-Cas9–mediated editing in a competitive murine transplantation model.
- 14 January 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (2) , 289-300
Open AccessComparative analysis of CRISPR-Cas9, lentiviral transduction, and base editing for sickle cell disease in a murine model
Sickle cell disease (SCD) is a red blood cell disorder caused by a mutation in the β-globin gene, leading to sickle hemoglobin polymerization under low oxygen conditions. Both CRISPR-Cas9 editing and lentiviral transduction have shown promising clinical outcomes, but it remains unclear which approach is superior. Alternatively, new editing tools such as base editing may also be promising and reduce risks of genotoxicity. To compare these approaches, we studied them in an immunocompromised mouse model. We optimized ex vivo conditions in CD34+ hematopoietic stem and progenitor cells (HSPC) and infused edited SCD HSPC into busulfan-conditioned nonirradiated NOD,B6.SCID Il2rγ−/−KitW41/W41 (NBSGW) mice. Ex vivo analysis confirmed successful editing and transduction. At 16 weeks, bone marrow analysis showed similar human CD45+ cell engraftment across all groups (75%-90%). In the competitive transplantation group, there was a lower amount of B-cell lymphoma/leukemia 11A enhancer editing than base editing and lentiviral transduction. A secondary transplantation model yielded similar results. An antisickling assay showed significantly higher red blood cell sickling reduction in the base editing, transduction, and competitive transplantation groups compared to CRISPR-Cas9. In conclusion, although all methods showed therapeutic potential, base editing and lentiviral transduction provided superior outcomes over CRISPR-Cas9–mediated editing in a competitive murine transplantation model.
- Open Access
- 1 April 2025
- Published by Elsevier in Molecular Therapy
- Vol. 33 (5) , 2154-2171
Genome editing strategies for targeted correction of β-globin mutation in sickle cell disease: From bench to bedside
- 1 April 2025
- Published by Elsevier in Molecular Therapy
- Vol. 33 (5) , 2154-2171
Open AccessGenome editing strategies for targeted correction of β-globin mutation in sickle cell disease: From bench to bedside
- 5 December 2024
- Published by Elsevier in Cell Stem Cell
- Vol. 32 (2) , 209-226.e8
BCL11A +58/+55 enhancer-editing facilitates HSPC engraftment and HbF induction in rhesus macaques conditioned with a CD45 antibody-drug conjugate
- 5 December 2024
- Published by Elsevier in Cell Stem Cell
- Vol. 32 (2) , 209-226.e8
BCL11A +58/+55 enhancer-editing facilitates HSPC engraftment and HbF induction in rhesus macaques conditioned with a CD45 antibody-drug conjugate
- Open Access
- 9 April 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (7) , 1806-1816
In vivo measurement of RBC survival in patients with sickle cell disease before or after hematopoietic stem cell transplantation
Stable, mixed-donor–recipient chimerism after allogeneic hematopoietic stem cell transplantation (HSCT) for patients with sickle cell disease (SCD) is sufficient for phenotypic disease reversal, and results from differences in donor/recipient–red blood cell (RBC) survival. Understanding variability and predictors of RBC survival among patients with SCD before and after HSCT is critical for gene therapy research which seeks to generate sufficient corrected hemoglobin to reduce polymerization thereby overcoming the red cell pathology of SCD. This study used biotin labeling of RBCs to determine the lifespan of RBCs in patients with SCD compared with patients who have successfully undergone curative HSCT, participants with sickle cell trait (HbAS), and healthy (HbAA) donors. Twenty participants were included in the analysis (SCD pre-HSCT: N = 6, SCD post-HSCT: N = 5, HbAS: N = 6, and HbAA: N = 3). The average RBC lifespan was significantly shorter for participants with SCD pre-HSCT (64.1 days; range, 35-91) compared with those with SCD post-HSCT (113.4 days; range, 105-119), HbAS (126.0 days; range, 119-147), and HbAA (123.7 days; range, 91-147) (P<.001). RBC lifespan correlated with various hematologic parameters and strongly correlated with the average final fraction of sickled RBCs after deoxygenation (P<.001). No adverse events were attributable to the use of biotin and related procedures. Biotin labeling of RBCs is a safe and feasible methodology to evaluate RBC survival in patients with SCD before and after HSCT. Understanding differences in RBC survival may ultimately guide gene therapy protocols to determine hemoglobin composition required to reverse the SCD phenotype as it relates directly to RBC survival. This trial was registered at www.clinicaltrials.gov as #NCT04476277.
- 9 April 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (7) , 1806-1816
Open AccessIn vivo measurement of RBC survival in patients with sickle cell disease before or after hematopoietic stem cell transplantation
Stable, mixed-donor–recipient chimerism after allogeneic hematopoietic stem cell transplantation (HSCT) for patients with sickle cell disease (SCD) is sufficient for phenotypic disease reversal, and results from differences in donor/recipient–red blood cell (RBC) survival. Understanding variability and predictors of RBC survival among patients with SCD before and after HSCT is critical for gene therapy research which seeks to generate sufficient corrected hemoglobin to reduce polymerization thereby overcoming the red cell pathology of SCD. This study used biotin labeling of RBCs to determine the lifespan of RBCs in patients with SCD compared with patients who have successfully undergone curative HSCT, participants with sickle cell trait (HbAS), and healthy (HbAA) donors. Twenty participants were included in the analysis (SCD pre-HSCT: N = 6, SCD post-HSCT: N = 5, HbAS: N = 6, and HbAA: N = 3). The average RBC lifespan was significantly shorter for participants with SCD pre-HSCT (64.1 days; range, 35-91) compared with those with SCD post-HSCT (113.4 days; range, 105-119), HbAS (126.0 days; range, 119-147), and HbAA (123.7 days; range, 91-147) (P<.001). RBC lifespan correlated with various hematologic parameters and strongly correlated with the average final fraction of sickled RBCs after deoxygenation (P<.001). No adverse events were attributable to the use of biotin and related procedures. Biotin labeling of RBCs is a safe and feasible methodology to evaluate RBC survival in patients with SCD before and after HSCT. Understanding differences in RBC survival may ultimately guide gene therapy protocols to determine hemoglobin composition required to reverse the SCD phenotype as it relates directly to RBC survival. This trial was registered at www.clinicaltrials.gov as #NCT04476277.
- 24 February 2024
- Published by Elsevier in Cytotherapy
- Vol. 26 (6) , 641-648
Ex vivo culture resting time impacts transplantation outcomes of genome-edited human hematopoietic stem and progenitor cells in xenograft mouse models
- 24 February 2024
- Published by Elsevier in Cytotherapy
- Vol. 26 (6) , 641-648
Ex vivo culture resting time impacts transplantation outcomes of genome-edited human hematopoietic stem and progenitor cells in xenograft mouse models
- Open Access
- 12 October 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-11
Fertility-preserving myeloablative conditioning using single-dose CD117 antibody-drug conjugate in a rhesus gene therapy model
Hematopoietic stem cell (HSC) gene therapy has curative potential; however, its use is limited by the morbidity and mortality associated with current chemotherapy-based conditioning. Targeted conditioning using antibody-drug conjugates (ADC) holds promise for reduced toxicity in HSC gene therapy. Here we test the ability of an antibody-drug conjugate targeting CD117 (CD117-ADC) to enable engraftment in a non-human primate lentiviral gene therapy model of hemoglobinopathies. Following single-dose CD117-ADC, a >99% depletion of bone marrow CD34 + CD90 + CD45RA- cells without lymphocyte reduction is observed, which results are not inferior to multi-day myeloablative busulfan conditioning. CD117-ADC, similarly to busulfan, allows efficient engraftment, gene marking, and vector-derived fetal hemoglobin induction. Importantly, ADC treatment is associated with minimal toxicity, and CD117-ADC-conditioned animals maintain fertility. In contrast, busulfan treatment commonly causes severe toxicities and infertility in humans. Thus, the myeloablative capacity of single-dose CD117-ADC is sufficient for efficient engraftment of gene-modified HSCs while preserving fertility and reducing adverse effects related to toxicity in non-human primates. This targeted conditioning approach thus provides the proof-of-principle to improve risk-benefit ratio in a variety of HSC-based gene therapy products in humans.
- 12 October 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-11
Open AccessFertility-preserving myeloablative conditioning using single-dose CD117 antibody-drug conjugate in a rhesus gene therapy model
Hematopoietic stem cell (HSC) gene therapy has curative potential; however, its use is limited by the morbidity and mortality associated with current chemotherapy-based conditioning. Targeted conditioning using antibody-drug conjugates (ADC) holds promise for reduced toxicity in HSC gene therapy. Here we test the ability of an antibody-drug conjugate targeting CD117 (CD117-ADC) to enable engraftment in a non-human primate lentiviral gene therapy model of hemoglobinopathies. Following single-dose CD117-ADC, a >99% depletion of bone marrow CD34 + CD90 + CD45RA- cells without lymphocyte reduction is observed, which results are not inferior to multi-day myeloablative busulfan conditioning. CD117-ADC, similarly to busulfan, allows efficient engraftment, gene marking, and vector-derived fetal hemoglobin induction. Importantly, ADC treatment is associated with minimal toxicity, and CD117-ADC-conditioned animals maintain fertility. In contrast, busulfan treatment commonly causes severe toxicities and infertility in humans. Thus, the myeloablative capacity of single-dose CD117-ADC is sufficient for efficient engraftment of gene-modified HSCs while preserving fertility and reducing adverse effects related to toxicity in non-human primates. This targeted conditioning approach thus provides the proof-of-principle to improve risk-benefit ratio in a variety of HSC-based gene therapy products in humans.
- Open Access
- 22 August 2023
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 30, 411-412
Toward effective hematopoietic stem cell gene therapies: Optimized conditioning regimen and stem cell source in harmony
- 22 August 2023
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 30, 411-412
Open AccessToward effective hematopoietic stem cell gene therapies: Optimized conditioning regimen and stem cell source in harmony